losartan and vitamin d 2

losartan has been researched along with vitamin d 2 in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (25.00)	29.6817
2010's	11 (68.75)	24.3611
2020's	1 (6.25)	2.80

Authors

Authors	Studies
Strassburg, CP; Tukey, RH	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Deb, DK; Kong, J; Li, YC; Ning, G; Zhang, Y; Zhang, Z	1
Müller, D; Müller, DN	1
Arbeeny, C; Chen, Y; Deb, DK; Kong, J; Li, G; Li, YC; Ning, G; Sabbagh, Y; Strugnell, S; Wang, Y; Zhang, Y; Zhang, Z	1
Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z	1
Agarwal, R	1
Bhan, I; Kim, GH; Kong, J; Li, G; Li, X; Li, YC; Liu, SQ; Sun, T; Thadhani, R; Wei, M; Zhao, Q	1
Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu	1
Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA	1
Biter, HI; Can, MM; Dinckal, MH; Erentug, V; Güngör, B; Kayalar, N; Mert, B; Okuyan, E; Ozkaynak, B; Sahin, I; Sar, M	1
Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F	1
Abbate, M; Belviso, A; Bossi, AC; Carrara, F; de Borst, M; Diadei, O; Gaspari, F; Iliev, IP; Parvanova, A; Peraro, F; Perna, A; Podestà, MA; Remuzzi, G; Rubis, N; Ruggenenti, P; Ruggiero, B; Stucchi, N; Trevisan, R; Trillini, M	1
Chang, J; Du, J; Ge, X; Li, X; Li, YC; Liu, W; Nie, H; Sun, Y; Wei, X; Xun, Z	1

Reviews

3 review(s) available for losartan and vitamin d 2

Article	Year
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual review of pharmacology and toxicology, 2000, Volume: 40 Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic	2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. Terapevticheskii arkhiv, 2011, Volume: 83, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Calcitriol; Cardiovascular Diseases; Chronic Disease; Ergocalciferols; Humans; Kidney Diseases; Losartan	2011

Trials

1 trial(s) available for losartan and vitamin d 2

Article	Year
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:1 Topics: Aged; Albuminuria; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Double-Blind Method; Drug Resistance; Ergocalciferols; Female; Humans; Italy; Losartan; Male; Middle Aged; Treatment Outcome	2018

Article

Year

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:1

Topics: Aged; Albuminuria; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Double-Blind Method; Drug Resistance; Ergocalciferols; Female; Humans; Italy; Losartan; Male; Middle Aged; Treatment Outcome

2018

Other Studies

12 other study(ies) available for losartan and vitamin d 2

Article	Year
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proceedings of the National Academy of Sciences of the United States of America, 2008, Oct-14, Volume: 105, Issue:41 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Combinations; Ergocalciferols; Losartan; Mice; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Streptozocin; Vitamin D	2008
Battle against the renin-angiotensin system: help from an unexpected party. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Ergocalciferols; Losartan; Mice; Renin-Angiotensin System; Vitamin D	2009
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:3 Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ergocalciferols; Fibrosis; Glomerular Basement Membrane; Inflammation Mediators; Losartan; Macrophages; Mice; Mice, Inbred DBA; Podocytes; Renin; Renin-Angiotensin System; Time Factors; Vitamins	2009
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney international, 2010, Volume: 77, Issue:11 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Drug Synergism; Drug Therapy, Combination; Ergocalciferols; Extracellular Matrix Proteins; Gene Expression Regulation; Inflammation Mediators; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Receptors, Leptin; Renin-Angiotensin System; RNA, Messenger; Time Factors; Vitamins	2010
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects? Kidney international, 2010, Volume: 77, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Synergism; Drug Therapy, Combination; Ergocalciferols; Extracellular Matrix Proteins; Humans; Inflammation Mediators; Kidney Glomerulus; Losartan; Mice; Receptors, Calcitriol; Renin-Angiotensin System; Vitamins	2010
Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. The American journal of pathology, 2010, Volume: 177, Issue:2 Topics: Aged; Animals; Antihypertensive Agents; Ergocalciferols; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Microarray Analysis; Middle Aged; Random Allocation; Rats; Rats, Inbred SHR; Renin; Vitamin D; Vitamins	2010
The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:3-5 Topics: Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Collagen Type III; Disease Models, Animal; Ergocalciferols; Fibronectins; Fibrosis; Gene Expression Regulation; Hypertrophy, Left Ventricular; Losartan; Male; Mice; Mice, Inbred C57BL; Myocardium; Tissue Inhibitor of Metalloproteinase-1; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling	2012
Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:19 Topics: Animals; Contrast Media; Disease Models, Animal; Drug Therapy, Combination; Ergocalciferols; Kidney Diseases; Losartan; Male; Rabbits; Rats; Rats, Wistar; Renin-Angiotensin System	2014
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 2015, Mar-06, Volume: 10, Issue:3 Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasentan; Bone Density Conservation Agents; Diabetic Nephropathies; Endothelin Receptor Antagonists; Ergocalciferols; Female; Fumarates; Humans; Losartan; Male; Middle Aged; Office Visits; Pyrrolidines; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic; Urine Specimen Collection	2015
Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung. Scientific reports, 2021, 08-16, Volume: 11, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Bleomycin; Disease Models, Animal; Ergocalciferols; Losartan; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; Pulmonary Fibrosis; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Transforming Growth Factor beta; Vitamin D	2021